Apogee Therapeutics to Participate in Upcoming March Conferences
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE) announced management will participate in three investor events in early March 2026: a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and attendance at the UBS Biotech Summit Miami (March 9) and Jefferies Biotech on the Beach Summit (March 10). A live and archived webcast of the March 3 fireside chat will be available on the company’s Investors News & Events page.
Positive
- None.
Negative
- None.
Details
News Market Reaction – APGE
In the Feb 24 session, APGE gained 1.95%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Share price
- $69.91
- Pre-news current price for APGE
- Daily move
- 2.22%
- Price change over prior 24 hours
- Volume today
- 723,868
- Shares traded on the session before this news
- 52-week high
- $84.56
- Upper end of 52-week trading range
- 52-week low
- $26.20
- Lower end of 52-week trading range
- Market cap
- $4,672,420,461
- Equity value before conference news
- Short interest
- 18.97%
- Reported short interest as a percent of float
- Days to cover
- 9.02
- Short interest divided by average daily volume
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 9:10 a.m. E.T. Management will also attend the UBS Biotech Summit Miami, Catalyst for Change on Monday, March 9, 2026, and the Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026.
A live and archived webcast of the fireside chat at the TD Cowen Conference will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart (APG777), the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets, as well as asthma. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
